MicroLine achieved the primary endpoint in the phase 3 VISION-1 clinical study, demonstrating temporary improvement of near vision in adults with presbyopia, according to a press release from Eyenovia.
“A statistically significant proportion of subjects treated with a therapeutic dose of MicroLine” achieved three or more lines of improvement in distance corrected near visual acuity in low light conditions at 2 hours compared with placebo, the release said.
The pilocarpine formulation was well tolerated. There were no serious adverse events, and any other adverse events were mild.
“We